{"transactions":[{"id":704706,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2026-07-22T20:05:22.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":64051,"price":7.7605,"value":497067.7855,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":741570,"source":{"system":"sec-edgar","filing":"0001193125-26-312397","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000119312526312397/ownership.xml","form_type":"4"}},{"id":757039,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T01:13:45.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":300000,"derivative":{"exercise_price":7.27,"expiration_date":"2036-05-27","underlying":"Series A Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001104659-26-069121","document":"tm2616578-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465926069121/tm2616578-1_4seq1.xml","form_type":"4"}},{"id":890656,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-20T21:41:03.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":256000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":256000,"derivative":{"exercise_price":5.38,"expiration_date":"2036-02-18","underlying":"Series A Common Stock","underlying_shares":256000},"source":{"system":"sec-edgar","filing":"0001104659-26-018193","document":"tm266959-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465926018193/tm266959-2_4seq1.xml","form_type":"4"}},{"id":890655,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2026-02-20T21:41:03.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":128000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":805621,"source":{"system":"sec-edgar","filing":"0001104659-26-018193","document":"tm266959-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465926018193/tm266959-2_4seq1.xml","form_type":"4"}},{"id":907549,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2026-02-12T21:08:51.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":12101,"price":5.3603,"value":64864.9903,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":677621,"source":{"system":"sec-edgar","filing":"0001104659-26-014283","document":"tm266207-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465926014283/tm266207-4_4seq1.xml","form_type":"4"}},{"id":1082784,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2025-07-23T20:16:25.000Z","date":"2025-07-21","kind":"sale","planned":false,"acquired":false,"shares":65478,"price":9.1346,"value":598115.3388,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":689722,"source":{"system":"sec-edgar","filing":"0001104659-25-070017","document":"tm2521574-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465925070017/tm2521574-3_4seq1.xml","form_type":"4"}},{"id":1278702,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-07T21:43:56.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":472000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":472000,"derivative":{"exercise_price":4.71,"expiration_date":"2035-02-05","underlying":"Series A Common Stock","underlying_shares":472000},"source":{"system":"sec-edgar","filing":"0001104659-25-010587","document":"tm255919-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465925010587/tm255919-3_4seq1.xml","form_type":"4"}},{"id":1278701,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2025-02-07T21:43:56.000Z","date":"2025-02-06","kind":"grant","planned":false,"acquired":true,"shares":116000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":755200,"source":{"system":"sec-edgar","filing":"0001104659-25-010587","document":"tm255919-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465925010587/tm255919-3_4seq1.xml","form_type":"4"}},{"id":1558400,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2024-03-28T20:08:37.000Z","date":"2024-03-26","kind":"purchase","planned":false,"acquired":true,"shares":12100,"price":5.267,"value":63730.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.24 per share to $5.2999 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each price."}],"balance_after":639200,"source":{"system":"sec-edgar","filing":"0001104659-24-040517","document":"tm2410115-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465924040517/tm2410115-1_4seq1.xml","form_type":"4"}},{"id":1717854,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2023-12-08T21:05:24.000Z","date":"2023-12-07","kind":"purchase","planned":false,"acquired":true,"shares":1600,"price":4.1,"value":6560.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.02 per share to $4.16 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each price."}],"balance_after":627100,"source":{"system":"sec-edgar","filing":"0001104659-23-124678","document":"tm2332520-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465923124678/tm2332520-1_4seq1.xml","form_type":"4"}},{"id":1732600,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2023-11-21T21:21:59.000Z","date":"2023-11-17","kind":"grant","planned":false,"acquired":true,"shares":624910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. 25% of the RSUs shall vest on July 18, 2024, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":625500,"source":{"system":"sec-edgar","filing":"0001104659-23-120372","document":"tm2331048-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465923120372/tm2331048-1_4seq1.xml","form_type":"4"}},{"id":1734463,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series A Common Stock","published_at":"2023-11-21T02:59:29.000Z","date":"2023-11-16","kind":"purchase","planned":false,"acquired":true,"shares":590,"price":2.35,"value":1386.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.31 per share to $2.40 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each price."}],"balance_after":590,"source":{"system":"sec-edgar","filing":"0001104659-23-120027","document":"tm2331267-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465923120027/tm2331267-1_4seq1.xml","form_type":"4"}},{"id":1825825,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-20T20:15:51.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":1011826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":1011826,"derivative":{"exercise_price":7.15,"expiration_date":"2032-10-16","underlying":"Series A Common Stock","underlying_shares":1011826},"source":{"system":"sec-edgar","filing":"0001104659-23-082722","document":"tm2321276-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465923082722/tm2321276-14_4seq1.xml","form_type":"4"}},{"id":1825824,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-20T20:15:51.000Z","date":"2023-07-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1011826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.15,"expiration_date":"2032-10-16","underlying":"Common Stock","underlying_shares":1011826},"source":{"system":"sec-edgar","filing":"0001104659-23-082722","document":"tm2321276-14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000110465923082722/tm2321276-14_4seq1.xml","form_type":"4"}},{"id":4180111,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Dev & Strategy"}}],"security":"Restricted Stock Units","published_at":"2017-10-26T23:39:36.000Z","date":"2017-10-25","kind":"exercise","acquired":false,"shares":7953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On October 25, 2016, the reporting person was granted an aggregate of 31,813 restricted stock units. The restricted stock units vest in four equal annual installments beginning on October 25, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On October 25, 2016, the reporting person was granted an aggregate of 31,813 restricted stock units. The restricted stock units vest in four equal annual installments beginning on October 25, 2017."}],"balance_after":23860,"derivative":{"underlying":"Ordinary Shares","underlying_shares":7953},"source":{"system":"sec-edgar","filing":"0001209191-17-058085","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000120919117058085/doc4.xml","form_type":"4"}},{"id":4180110,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Dev & Strategy"}}],"security":"Ordinary Shares","published_at":"2017-10-26T23:39:36.000Z","date":"2017-10-25","kind":"tax_withholding","acquired":false,"shares":4150,"price":13.53,"value":56149.5,"ownership":{"direct":true},"balance_after":5089,"source":{"system":"sec-edgar","filing":"0001209191-17-058085","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000120919117058085/doc4.xml","form_type":"4"}},{"id":4180109,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Commercial Dev & Strategy"}}],"security":"Ordinary Shares","published_at":"2017-10-26T23:39:36.000Z","date":"2017-10-25","kind":"exercise","acquired":true,"shares":7953,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,286 ordinary shares of the Issuer acquired by the reporting person on June 1, 2017 pursuant to an employee stock purchase program."}],"balance_after":9239,"source":{"system":"sec-edgar","filing":"0001209191-17-058085","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1623567/000120919117058085/doc4.xml","form_type":"4"}},{"id":4574174,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2016-10-26T16:41:27.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":93784,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.74,"expiration_date":"2026-02-09","underlying":"Common Stock","underlying_shares":93784},"source":{"system":"sec-edgar","filing":"0001140361-16-083653","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083653/doc1.xml","form_type":"4"}},{"id":4574173,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2016-10-26T16:41:27.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":28939,"price":9,"value":260451.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-16-083653","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083653/doc1.xml","form_type":"4"}},{"id":4574172,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":29160,"kind":"person","name":"Happel David","position":1,"cik":"0001623567","reported_name":"Happel David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2016-10-26T16:41:27.000Z","date":"2016-10-24","kind":"other","acquired":false,"shares":8934,"price":9,"value":80406.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. (\"Raptor\"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland (\"Parent\") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent."}],"balance_after":28939,"source":{"system":"sec-edgar","filing":"0001140361-16-083653","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083653/doc1.xml","form_type":"4"}}]}